First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection.

Mohamed Farouk ChughlayEmilie RossignolCristina DoniniMyriam El GaaloulUlrike LorchSimon CoatesGrant LangdonTim HammondJörg MöhrleStephan Chalon

Published in: British journal of clinical pharmacology (2020)

P218 displayed favourable safety, tolerability and pharmacokinetics. In view of its short half-life, a long-acting formulation will be needed for malaria chemoprotection.

Keyphrases

open label
clinical trial
plasmodium falciparum
double blind
endothelial cells
placebo controlled
phase ii
drug delivery
phase iii
randomized controlled trial